This is a snapshot of this mornings newsletter from Biophatma News. Not being paid subscriber I couldn’t access the full article But it’s interesting that it suggests that Bi-Specifics will soon surpass Keytruda .
It’s worth remembering our current OASIS trial in solid tumors . Is combing Oncarlytics with Blincyto which is a Bi-Specific which targets CD19.
We are at the very cutting edge of curing stage 3 and 4 cancers using our UNIVERSAL Vaccine against cancer.
Just listen to Yuman Fongs excitement in yesterday’s reposted video. He is so excited about Azer-Cel being a universal CarT therapy that will work in patients with burnt out immune systems.
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)